Evidence map›Paper›PMID 28663577›Full record

ArticleLeukemia2017

Preclinical modeling of myelodysplastic syndromes.

K Rouault-Pierre, S A Mian, M Goulard, A Abarrategi, A Di Tulio, A E Smith, A Mohamedali, S Best, A-M Nloga, A G Kulasekararaj and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Humanized mouse models in MDS.Cell death & disease · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. The Mesenchymal Niche in Myelodysplastic Syndromes.Diagnostics (Basel, Switzerland) · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. [Advances on mouse transplantation model of myelodysplastic syndrome].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

K Rouault-PierreHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK.
S A MianHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK.
M GoulardINSERM, UMRS1131-University Paris Diderot, Saint Louis Hospital, Paris, France.
A AbarrategiHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK.
A Di TulioHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK.
A E SmithKing's College London School of Medicine, Department of Haematological Medicine, London, UK.
A MohamedaliKing's College London School of Medicine, Department of Haematological Medicine, London, UK.
S BestKing's College London School of Medicine, Department of Haematological Medicine, London, UK.
A-M NlogaSenior Haematology Department, Saint Louis Hospital, APHP, Paris, France.
A G KulasekararajKing's College Hospital, Department of Haematology, London, UK.
L AdesSenior Haematology Department, Saint Louis Hospital, APHP, Paris, France.
C ChomienneINSERM, UMRS1131-University Paris Diderot, Saint Louis Hospital, Paris, France.
P FenauxINSERM, UMRS1131-University Paris Diderot, Saint Louis Hospital, Paris, France.
C DosquetINSERM, UMRS1131-University Paris Diderot, Saint Louis Hospital, Paris, France.
G J MuftiKing's College London School of Medicine, Department of Haematological Medicine, London, UK.
D BonnetHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-4735-5226
King's College London · GBInserm · FRThe Francis Crick Institute · GBAssistance Publique – Hôpitaux de Paris · FRKing's College Hospital · GB

Funding

Cancer Research UK 15692
6 · The paper itself

Abstract

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological clonal disorders. Here, we have tested the bone marrow (BM) cells from 38 MDS patients covering all risk groups in two immunodeficient mouse models: NSG and NSG-S. Our data show comparable level of engraftment in both models. The level of engraftment was patient specific with no correlation to any specific MDS risk group. Furthermore, the co-injection of mesenchymal stromal cells (MSCs) did not improve the level of engraftment. Finally, we have developed an in vitro two-dimensional co-culture system as an alternative tool to in vivo. Using our in vitro system, we have been able to co-culture CD34

Indexed as

AnimalsBiomarkersBone Marrow CellsBone Marrow TransplantationChromosome AberrationsDisease Models, AnimalFemaleGene ExpressionGenes, ReporterHeterograftsHumansImmunophenotypingMaleMesenchymal Stem CellsMiceMice, KnockoutBiomarkers

Identifiers

PMID28663577
PMCPMC5729336
OpenAlexW2621350181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.